KRAS and non-small cell lung carcinoma: Furthermore, a previous study reported that patients diagnosed with advanced KRAS-mutant NSCLC undergoing therapy with adagrasib that presented clearance in KRAS-clones showed improved survival (14.1 months vs 8.7 months; P = .04; HR = 0.3).44 This evidence suggests that a mutation-based longitudinal ctDNA assessment may predict treatment response.